• 1. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890
• 2. Fc microparticles can modulate the physical extent and magnitude of complement activity?
  David White,Sean R. Stowell Biomater. Sci., 2017,5, 463-474
• 3. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 4. Enantio- & chemo-selective preparation of enantiomerically enriched aliphatic nitro alcohols using Candida parapsilosis ATCC 7330
  Sowmyalakshmi Venkataraman RSC Adv., 2015,5, 73807-73813
• 5. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives 2-pyridylmethylamines

Recent Advances in the Study of 5-Bromo-2-piperidin-1-ylmethyl-pyridine (CAS: 364794-78-5)

The compound 5-bromo-2-piperidin-1-ylmethyl-pyridine (CAS: 364794-78-5) has garnered significant attention in recent years due to its potential applications in medicinal chemistry and drug discovery. This heterocyclic compound, characterized by a brominated pyridine core and a piperidine substituent, has been explored for its role as a versatile intermediate in the synthesis of bioactive molecules. Recent studies have focused on its utility in the development of kinase inhibitors, neurotransmitter modulators, and antimicrobial agents, highlighting its broad pharmacological relevance.

One of the key areas of research involving 5-bromo-2-piperidin-1-ylmethyl-pyridine is its incorporation into small-molecule libraries for high-throughput screening. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its efficacy as a scaffold for designing selective inhibitors of protein kinases implicated in cancer progression. The study utilized structure-activity relationship (SAR) analysis to optimize the compound's binding affinity, resulting in derivatives with nanomolar potency against specific kinase targets. These findings underscore the compound's potential as a lead structure in oncology drug development.

In addition to its role in kinase inhibition, 5-bromo-2-piperidin-1-ylmethyl-pyridine has been investigated for its interactions with central nervous system (CNS) receptors. A recent preprint on bioRxiv detailed its use in synthesizing analogs targeting the serotonin and dopamine receptor families. Preliminary in vitro assays revealed moderate affinity for 5-HT_2A and D₂ receptors, suggesting possible applications in neuropsychiatric disorders. However, further in vivo studies are needed to validate these effects and assess blood-brain barrier permeability.

The synthetic accessibility of 5-bromo-2-piperidin-1-ylmethyl-pyridine has also been a focus of recent methodological advancements. A 2024 Organic Letters publication described a novel one-pot coupling strategy using palladium-catalyzed C-N bond formation, which improved the yield of the compound by 35% compared to traditional routes. This innovation addresses scalability challenges and enhances its viability for industrial-scale production, particularly in the context of fragment-based drug design.

Despite these promising developments, challenges remain in fully elucidating the compound's safety profile and off-target effects. Toxicological studies reported in Chemical Research in Toxicology (2023) identified potential hepatotoxicity at high concentrations, emphasizing the need for structural modifications to improve selectivity. Computational modeling approaches, such as molecular dynamics simulations, are being employed to predict and mitigate these adverse effects while preserving the compound's therapeutic potential.

Looking ahead, the versatility of 5-bromo-2-piperidin-1-ylmethyl-pyridine positions it as a valuable tool in chemical biology and drug discovery pipelines. Ongoing research aims to expand its applications to infectious disease targets, with early-stage investigations reporting activity against bacterial efflux pumps. As synthetic methodologies and biological evaluations continue to evolve, this compound is poised to contribute significantly to the development of next-generation therapeutics across multiple disease areas.

• 62426-06-6(1H-Pyrrole, 4-bromo-2-(1-pyrrolidinylmethyl)-)
• 869349-05-3(2-PYRIDINEMETHANAMINE, 5-BROMO-N,N-BIS(2-PYRIDINYLMETHYL)-)
• 364794-76-3(PIPERAZINE, 1-[(5-BROMO-2-PYRIDINYL)METHYL]-4-ETHYL-)
• 100693-39-8(1-Azoniabicyclo[2.2.2]octane, 1,1'-[2,6-pyridinediylbis(methylene)]bis-, dibromide)
• 886854-29-1(PYRIDINE, 2,6-BIS(1-PIPERIDINYLMETHYL)-)
• 364794-75-2(Piperazine, 1-[(5-bromo-2-pyridinyl)methyl]-4-methyl-)
• 71172-77-5(2-(piperidin-1-ylmethyl)pyridine)
• 915707-70-9(N-Methyl-(5-bromopyrid-2-yl)methylamine)
• 168823-71-0(Pyridine, 5-bromo-2-(1-pyrrolidinylmethyl)-)
• 908271-69-2([(5-bromopyridin-2-yl)methyl]dimethylamine)